Abstract
Renin Angiotensin Aldosterone System (RAAS) blockade is known to foster renoprotection in patients with both diabetic and non-diabetic proteinuric chronic kidney disease (CKD). Nonetheless, there continues considerable dispute and disagreement concerning renal and cardiovascular (CV) outcomes when concurrent RAAS blockade is discontinued in patients with advanced CKD. There are conflicting reports on renal and CV outcomes with RAAS blockade discontinuation in advanced CKD. Whereas there is general agreement that estimated glomerular filtration rate (eGFR) often improves, following such discontinuation, most of the studies have reported increased mortality and worse CV outcomes.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
